Pediatric Neurogenic Bladder Clinical Practice Guidelines (2019)

European Association of Urology and European Society for Pediatric Urology

This is a quick summary of the guidelines without analysis or commentary. For more information, go directly to the guidelines by clicking the link in the reference.

December 03, 2019

The guidelines on management of neurogenic bladder in children and adolescents were released in November 2019 by the European Association of Urology and the European Society for Pediatric Urology.[1]

In newborns with spina bifida, clean intermittent catheterization (CIC) should be started as soon as possible after birth.

In those with intrauterine closure of the defect, urodynamic studies should be performed before the patient leaves the hospital.

In those with closure after birth, urodynamics should be done within the next 3 months.

Anticholinergic medication (oxybutynin is the only well-investigated drug in this age group—dosage 0.2-0.4 mg/kg/day) should be administered if the urodynamic study confirmed detrusor overactivity.

Close follow-up—including ultrasound, bladder diary, urinalysis, and urodynamics—is necessary in the first 6 years. After that time the frequency of follow-up can be reduced, depending on the individual risk and clinical course.

In all other children with the suspicion of a neurogenic bladder (eg, due to tethered cord, inflammation, tumors, trauma, or other reasons), as well as those with anorectal malformations, urodynamics—preferably video-urodynamics—should be carried out as soon as suspicion of a neurogenic bladder arises, and conservative treatment should be started soon after confirmation of the diagnosis of neurogenic bladder.

With conservative treatment, the upper urinary tract is preserved in up to 90% of patients; urinary tract infections are common but not severe, complications of CIC are quite rare, and continence can be achieved at adolescence in up to 80% without further treatment.

For more information, see Spina Bifida and Neurogenic Bladder. For more Clinical Practice Guidelines, please go to Guidelines.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....